Published online Jul 9, 2022. doi: 10.5409/wjcp.v11.i4.330
Peer-review started: December 13, 2021
First decision: March 24, 2022
Revised: March 24, 2022
Accepted: April 28, 2022
Article in press: April 28, 2022
Published online: July 9, 2022
Processing time: 205 Days and 6.4 Hours
Irritable bowel syndrome (IBS) has a significant effect on the lives of affected children and their families and poses a substantial burden on healthcare systems. A few potential therapeutic modalities are available to treat children with IBS, and fewer of them have shown some benefits.
A few potential therapeutic modalities are available to treat children with IBS, and fewer of them have shown some benefits. The authors need to conduct more studies to help patients with IBS alleviate their symptoms.
The authors aimed to study the effects of the Mediterranean diet on the symptoms of IBS in children and adolescents.
The authors studied one hundred consecutive IBS patients diagnosed according to Rome IV criteria, aged 12-18 years old. The authors divided the patients into two groups (50 patients each), the group I received a Mediterranean diet with good adherence (KIDMED Score ≥ 8 points), and Group II received a regular diet.
IBS children and adolescents with good adherence to the Mediterranean diet (KIDMED Score ≥ 8 points); group I showed significant improvement in IBS scores. IBS-SSS in the Mediterranean diet group was 237.2 ± 65 at the beginning of the study and decreased to 163.2 ± 33.8 at the end of the study (P < 0.001). It did not show a significant improvement in the group with a regular diet (248.3 ± 71.1 at the beginning of the study compared to 228.5 ± 54.3 at the study end with P < 0.05). The mean IBS-SSS in the Mediterranean diet group significantly improved compared with the group with a regular diet. Mean IBS-QoL in group I improved from 57.3 ± 12.9 at the start of the study to 72.4 ± 11.2 at the study end (P < 0.001) and significantly improved when compared to its level in group II at the study end (59.2 ± 12.7) with P < 0.001, while group II showed no significant improvement in IBS-QoL at the study end when compared to the beginning of the study (59.2 ± 11.7 with P > 0.05). The mean total IBS score in group I became 28.8 ± 11.2 at the end of our study compared to 24.1 ± 10.4 at the start (P < 0.05) and significantly improved when compared to its level in group II at the end of the study (22.1 ± 12.5) with P < 0.05, while in group II, non-significant improvement in the total score at the end of our study compared to its mean level at the start of the study (22.8 ± 13.5) with P > 0.05.
Mediterranean diet was safe and associated with significant improvement in IBS scores in children and adolescent patients with IBS.
The authors need to extend our study for a longer duration. We also need to investigate the effects of the Mediterranean diet on the various GIT functions, including bowel movement, stool consistency, and the impact on the gut microbiota.